API | lirilumab

lirilumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank

Active Ingredient History

NOW

Now

Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
lirilumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Killer cell immunoglobulin-like receptor 2DL1 (Homo sapiens) ^UniProt
- Killer cell immunoglobulin-like receptor 2DL2 (Homo sapiens) ^UniProt
- Killer cell immunoglobulin-like receptor 2DL3 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

anti-kir antibody | bms-986015 | bms-986015-01 | iph2102 | lirilumab

Organizations (8)

Research & Development (8)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Hodgkin Disease (Phase 1)

Leukemia (Phase 2)

Leukemia, Biphenotypic, Acute (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Urinary Bladder Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 13
# of Trial Organizations: 8

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue